12th October, 2020 – Destiny Pharma issued an announcement, which is summarized as follows:
101 patients
recruited in Phase 2b clinical study of lead asset XF-73 for the prevention of
postsurgical infections
Recruitment on track
to complete by year-end and report results in Q1 2021
Destiny Pharma today announces an update on its XF-73 Phase 2b clinical study with 101 patients out
of the target of 125 now recruited.
The Phase 2b clinical study is recruiting patients undergoing open heart surgery in United States and
Europe. Subject to recruitment being slowed again by the impact of COVID-19, the study is expected to complete recruitment before the end of the year and report results in Q1 2021.
Neil Clark, Chief Executive Officer of Destiny Pharma, said: “We are very pleased to report that we have passed the one hundred patients mark in our lead clinical study testing XF-73 as a novel product preventing the incidence of post-surgical infections. This follows a protocol amendment with the FDA and promising interim safety data announced earlier in the year. We expect to complete recruitment before
the end of the year and report results in early 2021 as we start preparations for the Phase 3 study.”
Original website Link: